A diagnostic protocol for autism: an Italian experience

Abstract

Background and aims: The usefulness of a protocol for aetiologic diagnosis in pervasive developmental disorders (PDD) has been considered in literature and the results are heterogeneous. We addressed this topic, evaluating an Italian sample of patients with PDD.

Material and methods: We included in the study the patients referred to the Autism Centre of the University of Bologna from January 1999 to September 2009, affected by PDD according to DSM-IV-TR. All the subjects underwent anamnesis, clinical, laboratory and instrumental investigations for an aetiological diagnosis. First, we evaluated neurobiological findings in the whole sample. After, we divided the patients into two groups, respectively syndromal (with genetic or metabolic syndromes, cerebral lesions and/or microcrania/macrocrania) and non-syndromal (without genetic, metabolic diseases, cerebral lesions and/or microcrania/macrocrania), that we compared each other for several variables.

Results: We selected 90 subjects (mean age 11 years 1 month, range 2-36 years, mean follow-up 3 years 8 months), respectively with autistic disorder (55.5%), pervasive developmental disorder not otherwise specified (38.9%), Asperger disorder (4.4%), Rett disorder (1.1%). Male-to-female ratio was 3:1. Organic pre-, peri-, and postnatal antecedents were found in 27.8% of subjects. Neurological signs were present in 83.3%; brain imaging showed pathological findings in 33.3%. Genetic examinations disclosed abnormal karyotype in 7.8%, one patient had the Cowden syndrome, one the Rett disorder variant CDKL5, one the Wilson-Turner syndrome. The syndromal group consisted of 42 subjects (46.7%), the non-syndromal one of 48 patients (53.3%). Dysmorphisms prevailed significantly in the syndromal cases (30.9%), but they were present also in 10.4% of the non-syndromal ones. Severe/profound mental retardation recurred more often in syndromal cases respect to non-syndromal ones (42.9% vs 29.2%), but the difference was not significant. We found epilepsy in 30.0% of the whole sample without a significant group difference.

Conclusion: The identification of specific pathologies underlying PDD could help to provide a medical therapy in tractable conditions, and to give a genetic counselling. In our sample genetic examinations, MRI and EEG recordings had the best diagnostic yield, while metabolic tests and other examinations were negative or mildly altered. Diagnostic evaluation should be performed choosing the examinations based on clinical suspicion with minimal resources and patient discomfort and with the best diagnostic yield.

Keywords

• pervasive developmental disorders
• autism
• genetics
• mental retardation
• epilepsy
• neurobiology

Kaynakça

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.
2. Fombonne E. Epidemiology of pervasive developmental disorders. Pediatr Res. 2009; 65: 591-8.
3. Johnson CP, Myers SM, the Council on Children With Disabilities. Identification and evaluation of children with autism spectrum disorders. Pediatrics. 2007; 120: 1183-215.
4. Schaefer GB, Mendelsohn NJ, the Professional Practice and Guidelines Committee. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders. Genet Med. 2008; 10: 301-5.
5. Kanner L. Autistic disturbances of affective contact. Nervous Child. 1943; 2: 217-50.
6. Giovanardi Rossi P, Parmeggiani A, Bach V, Santucci M, Visconti P. EEG features and epilepsy in patients with autism. Brain Dev. 1995; 17: 169-74.
7. Gillberg C, Coleman M. The Biology of the Autistic Syndromes. 2nd Edition. New York: Cambridge University Press; 1992.
8. Benvenuto A, Moavero R, Alessandrelli R, Manzi B, Curatolo P. Syndromic autism: causes and pathogenetic pathways. World J Pediatr. 2009; 5: 169-76.

9. Tuchman R, Rapin I. Autism: a Neurological Disorder of Early Brain Development. London: Mac Keith Press for the ICNA; 2006.
10. Pinto D, Pagnamenta AT, Klei L, Anney R, Merico D, Regan R, et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature. 2010; 466: 368-72.
11. Madsen KM, Hviid A, Vestergaard M, Schendel D, Wohlfahrt J, Thorsen P, et al. A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med. 2002; 347: 1477-82.
12. Dodds L, Fell DB, Shea S, Armson BA, Allen AC, Bryson S. The role of prenatal, obstetric and neonatal factors in the development of autism. J Autism Dev Disord. 2011; 41: 891-902. 10
13. Muhle R, Trentacoste SV, Rapin I. The genetics of autism. Pediatrics. 2004; 113: e472-e86.
14. Skjeldal OH, Sponheim E, Ganes T, Jellum E, Bakke S. Childhood autism: the need for physical investigations. Brain Dev. 1998; 20: 227-33.
15. Rapin I. Appropriate investigations for clinical care versus research in children with autism. Brain Dev. 1999; 21: 152-6.
16. Battaglia A, Carey JC. Etiologic yield of autistic spectrum disorders: a prospective study. Am J Med Genet C Semin Med Genet. 2006; 142C: 3-7.
17. Giovanardi Rossi P, Posar A, Parmeggiani A. Disturbi pervasivi dello sviluppo (DPS): protocollo di ricerca clinica ed eziologica. Gior Neuropsich Età Evol. 2001; 21: 273-307.
18. Giovanardi Rossi P, Posar A, Scaduto MC, Sangiorgi S, Cesaroni developmental disorders: clinical aspects and biological factors in a series of 331 patients. In: Elia M, Romano V, Curatolo P, editors. Consensus in Child Neurology: 5th Consensus Conference on Biological Bases and Clinical Perspectives in Autism. Hamilton, ON: BC Decker, 2002: 51-6. S, et al. Pervasive
19. Filipek PA, Accardo PJ, Ashwal S, Baranek GT, Cook EH Jr, Dawson G, et al. Practice parameter: screening and diagnosis of autism: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Child Neurology Society. Neurology. 2000; 55: 468-79.
20. Abdul-Rahman OA, Hudgins L. The diagnostic utility of a genetics evaluation in children with pervasive developmental disorders. Genet Med. 2006; 8: 50-4.
21. Herman GE, Henninger N, Ratliff-Schaub K, Pastore M, Fitzgerald S, McBride KL. Genetic testing in autism: how much is enough? Genet Med. 2007; 9: 268-74.
22. Schaefer GB, Starr L, Pickering D, Skar G, Dehaai K, Sanger WG. Array comparative genomic hybridization findings in a cohort referred for an autism evaluation. J Child Neurol. 2010; 25: 1498-503.
23. Verhoeven JS, De Cock P, Lagae L, Sunaert S. Neuroimaging of autism. Neuroradiology. 2010; 52: 3- 14.
24. Cohen D, Pichard N, Tordjman S, Baumann C, Burglen L, Excoffier E, et al. Specific genetic disorders and autism: clinical contribution towards their identification. J Autism Dev Disord. 2005; 35: 103-16.
25. Guitart-Feliubadaló M, Brunet-Vega A, Villatoro- Gómez S, Baena-Díez N, Gabau-Vila E. Chromosomal causes that produce mental retardation: chromosome disorders that can be diagnosed in the patient. Rev Neurol. 2006; 42 Suppl 1: S21-6.
26. Parmeggiani A, Posar A, Antolini C, Scaduto MC, Santucci M, Giovanardi Rossi P. Epilepsy in patients with pervasive developmental disorder not otherwise specified. J Child Neurol. 2007; 22: 1198-203.
27. Parmeggiani A, Barcia G, Posar A, Raimondi E, Santucci M, Scaduto MC. Epilepsy and EEG paroxysmal abnormalities in autism spectrum disorders. Brain Dev. 2010; 32: 783-9.
28. Bremer A, Giacobini M, Eriksson M, Gustavsson P, Nordin V, Fernell E, et al. Copy number variation characteristics in subpopulations of patients with autism spectrum disorders. Am J Med Genet B Neuropsychiatr Genet. 2011; 156: 115-24.
29. Kayser MA. Inherited metabolic diseases in neurodevelopmental and neurobehavioral disorders. Semin Pediatr Neurol. 2008; 15: 127-31.
30. Lintas C, Persico AM. Autistic phenotypes and genetic testing: state-of-the-art for the clinical geneticist. J Med Genet. 2009; 46: 1-8.
31. Roach ES, Sparagana SP. Diagnosis of tuberous sclerosis complex. J Child Neurol. 2004; 19: 643-9.